首页> 外文期刊>海南医科大学学报(英文版) >Clinical control effect analysis of intravenous infusion of lidocaine and dexmedetomidine for prevention and treatment of CRBD
【24h】

Clinical control effect analysis of intravenous infusion of lidocaine and dexmedetomidine for prevention and treatment of CRBD

机译:静脉注射利多卡因和德Xmedetomidine预防和治疗CRBD的临床控制效果分析

获取原文
获取原文并翻译 | 示例
       

摘要

Objective To investigate the clinical value of intravenous lidocaine in reducing CRBD in male patients who need catheterization after general anesthesia.Methods A total of 210 male patients who underwent elective general anesthesia in our hospital from May 2017 to April 2018 were selected.Random number table method was used to divide into the lidocaine group(1.5 mg?kg-1 of intravenous lidocaine infusion during anesthesia induction,and continuous intravenous infusion of lidocaine 2 mg?kg-1?h-1 after intubation),Dexmedetomidine group(0.5μg?kg-1 of dexmedetomidine intravenously during anesthesia induction,continuous intravenous infusion of dexmedetomidine 0.4μg?kg-1?h-1 after intubation).Control group(intravenous saline infusion during anesthesia induction,continuous intravenous infusion of the same amount of saline after intubation),70 cases in each group.All three groups were placed in the bladder with a 16F comfortable urethral catheter lubricated with paraffin oil.The amount of sufentanil used during the operation,the amount of sufentanil used after surgery,and the CRBD score and VAS at different time points after extubation were compared.Scoring,HR,SBP.Results T1 to T4,the CRBD scores of the lidocaine group were lower than those of the dexmedetomidine group and the control group(P<0.05).The VAS scores of the lidocaine group were lower than those of the control group(P<0.05),the CRBD score and VAS score of the dexmedetomidine group were lower than those of the control group(P<0.05);From T0 to T4,the differences in HR and SBP between the three groups were not statistically significant(P>0.05).Conclusion Lidocaine administration in male patients requiring catheterization after general anesthesia can significantly reduce the incidence of CRBD.
机译:目的探讨静脉利多卡因在一般麻醉后需要导尿的男性患者中CRBD的临床价值。在2017年5月至2018年5月,我们医院接受了210名男性患者的210名男性患者.Random编号表方法用于分为利多卡因组(在麻醉诱导期间静脉注射静脉注射Lidiocaine输注的1.5毫克kg-1,并且在插管后连续静脉输注Lid Caine 2 mg?H-1),Dexmedetomidine组(0.5μg≤kg -1在麻醉诱导过程中静脉内甲基丁络胺,在插管后连续静脉内输注右甲基甲基胺0.4μg≤KG-1?H-1)。控制组(麻醉期间静脉注射诱导,插管后连续静脉内输注相同量的盐水)每组70例。所有三组都置于膀胱中,配备16个舒适的尿道导管,润滑石蜡油。适量的量在操作期间使用的anil,进行了拔管后手术后使用的Sufentanil的量,以及在拔管后不同时间点的CRBD评分和VAS。速度,HR,SBP.results T1至T4,LIDocaine组的CRBD分数低于Dexmedetomidine组和对照组的那些(P <0.05)。利多卡因组的VAS分数低于对照组(P <0.05),右甲酰胺基团的CRBD得分和VAS得分低于那些对照组(P <0.05);从T0到T4,三组之间的HR和SBP的差异没有统计学意义(P> 0.05)。在一般麻醉后需要导尿患者的男性患者的合并利多卡因给药可以显着减少发病率CRBD。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号